Fate Therapeutics (FATE) Receives a Hold from Wedbush

Wedbush analyst David Nierengarten maintained a Hold rating on Fate Therapeutics (FATE – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1.00.

Confident Investing Starts Here:

• Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, AnaptysBio, and Nuvation Bio. According to TipRanks, Nierengarten has an average return of 5.7% and a 40.33% success rate on recommended stocks.

In addition to Wedbush, Fate Therapeutics also received a Hold from Needham’s Gil Blum in a report issued today. However, on the same day, Barclays maintained a Buy rating on Fate Therapeutics (NASDAQ: FATE).

FATE market cap is currently $122.6M and has a P/E ratio of -0.61.